Navigation Links
Neurocrine Biosciences Reports Third Quarter 2009 Results
Date:10/28/2009

cessed via the webcast through the Company's website at http://www.neurocrine.com

If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 1-800-723-2156 (US) or 402-220-2660 (International) using the passcode 7NEURO. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program, R & D pipeline and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH program include risk that the elagolix clinical trials will fail to demonstrate that elagolix is safe and effective; risk that elagolix will not proceed to later stage clinical trials; and risks associated with the Company's dependence on corporate c
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
2. Neurocrine Biosciences Presents Elagolix Data
3. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
6. Neurocrine Biosciences Reports First Quarter 2008 Results
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
11. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets has announced the addition of the ... to their offering. This report analyzes the ... following three major Application Areas: General/Abdominal Surgery, Pelvic/Gynecological Surgery, and ... analytics for the US, Canada , ... Asia-Pacific , Latin America , ...
(Date:8/19/2014)... 19, 2014 ,Weight Loss- Market ... 2014, report provides comprehensive insights about phase III pipeline ... objective of the report is to establish the understanding ... drugs across the different countries and regions. While the ... report also provides details on the drug master filings ...
(Date:8/18/2014)... Elbit Imaging Ltd. ("EI" or ... today that Elbit Medical Technologies Ltd. ("Elbit Medical") (TASE: ... holds approximately 86% of the voting power, announced that ... Elbit Medical holds approximately 30.8% of the voting power ... shareholders (including Elbit Medical), signed Option and Investment Agreements ...
Breaking Medicine Technology:Global Anti-Adhesion Products - Strategic Business Report 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 3
... to the FDA, LAUSANNE, Switzerland, November ... development specialist that,focuses on serious medical conditions ... its Canadian affiliate, filed its Complete,Response to ... States (U.S.),Food and Drug Administration (FDA) for ...
... ANTIPOLIS, France, November 4 NicOx,S.A. (Euronext Paris: ... patient Ambulatory Blood Pressure Monitoring (ABPM) trial (the ... of escalating,doses of naproxcinod and naproxen in osteoarthritis ... was the mean 24-hour,ambulatory systolic blood pressure (SBP) ...
Cached Medicine Technology:Sanvar(R) (Debio 8609) for Esophageal Variceal Bleeding 2Sanvar(R) (Debio 8609) for Esophageal Variceal Bleeding 3NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study 2NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study 3NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study 4
(Date:8/19/2014)... August 20, 2014 Top10BestSEOHosting.com has ... JustHost are the recommended suppliers for the webmasters ... hosting products. , According to the senior spokesman ... the most affordable hosting products on the market ... offer a variety of online deals when service ...
(Date:8/19/2014)... August 19, 2014 “ Inbox Blueprint ... course designed to provide users with the tools necessary ... marketing techniques and strategies. The course which was ... of excitement throughout the internet marketing world. The commotion ... HonestyFirstReviews.com's Tiffany Hendricks prompting an updated review of the ...
(Date:8/19/2014)... August 19, 2014 Horizon Blue Cross Blue ... Morgan Hoffmann are once again teaming up during The ... cause through a Walking Challenge, and Horizon BCBSNJ will be ... a course challenge of their own. , Horizon BCBSNJ, the ... is making a $5,000 donation to the New Jersey Golf ...
(Date:8/19/2014)... (HealthDay News) -- Lupus and other rheumatic diseases ... seizures, which can delay a correct diagnosis for ... rheumatic diseases can also cause these types of ... Center in Maywood, Ill. Rheumatic disorders include ... soft tissues, such as lupus, systemic vasculitis and ...
(Date:8/19/2014)... 2014 Grande Naturals, LLC is ... of the 2014 Independent Cosmetics Manufacturers & Distributors ... place position in “Product Innovation; Product Color Cosmetic” ... also includes a lash enhancement serum, GrandeLINER™. ... technology. , This all-new eyeliner is ...
Breaking Medicine News(10 mins):Health News:Fatcow Awarded As One of the Best Web Hosting Suppliers at Top10bestseohosting.com 2Health News:Anik Singal’s “Inbox Blueprint” Review Released By HonestyFirstReviews.com 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 3Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 4Health News:Certain Symptoms Can Delay Lupus Diagnosis, Researchers Report 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3
... today that it has dosed its first patient in ... ALT-2074, its lead glutathione peroxidase mimetic, in diabetic ... at high risk for cardiovascular complications. , ... ability to lower inflammatory cardiovascular biomarkers in patients with ...
... (JCVI) today announced the results of work on genome ... bacteria into another type dictated by the transplanted chromosome. ... journal Science, by JCVI's Carole Lartigue, Ph.D. and colleagues, ... bacterial species, Mycoplasma capricolum into another, Mycoplasma mycoides Large ...
... Businesses that offer customers shisha water pipes to smoke tobacco ... smoking ban that comes into force in England on Sunday. ... the water pipes are variously called, dozens of restaurants will ... see their sole activity disappear. ,"It's a disaster, ...
... name, one might rhetorically ask. But Malaccan state authorities have ... after their region. And now the virus will carry some ... announced last week they discovered a new virus likely carried ... called it the Melaka Virus, using the name of the ...
... with most other developing countries, plastic bags have become a terrible ... to be spiraling out of control, the government has announced a ... Uganda they are called buveera , and they are everywhere. ... organized dump like the one at Chitezi in Ugandan capital Kampala. ...
... found that nonsmoking restaurant and bar employees absorb a ... in places where they had to breathe tobacco smoke ... in the body only as a result of using ... the Multnomah County Health Department and Oregon Department of ...
Cached Medicine News:Health News:Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2 2Health News:First Bacterial Genome Transplantation Changing One Species to Another 2Health News:Shisha Owners Mobilise Against July 1 Smoking Ban in England 2Health News:Shisha Owners Mobilise Against July 1 Smoking Ban in England 3Health News:Mealaka Virus Will Have a New Name 2Health News:Uganda Bans Plastic Bags, Still a Tough Battle Lies Ahead 2Health News:Non Smoking Workers Absorb the Carcinogen Immediately 2Health News:Non Smoking Workers Absorb the Carcinogen Immediately 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: